MetaCap

Oncolytics Biotech (ONCY) vs Tonix Pharmaceuticals (TNXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oncolytics Biotech (ONCY) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 65.0% versus a loss of 85.2%. Over five years, ONCY leads with a -80.7% price change compared with -100.0% for TNXP. Oncolytics Biotech is the larger company by market cap ($47.7 million vs $46.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ONCY-64.99%TNXP-85.22%
+33%-29%-91%
Nov 21, 20251 yearNov 20, 2026
ONCY-79.88%TNXP-100.00%
+85%-12%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ONCY versus TNXP key metrics
MetricONCYTNXP
Share price$0.3501$2.38
Market cap$47.66M$46.25M
1-day change-10.37%-6.67%
YTD return-59.76%-84.76%
1-year return-64.99%-85.22%
5-year return-80.66%-100.00%
EPS (TTM)$-0.33$-12.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.11M
Revenue growth (YoY)—+29.85%
Net income (latest FY)$-28.76M$-124.02M
Gross margin—49.34%
Operating margin—-959.05%
Net margin—-946.22%
52-week high$1.30$20.56
52-week low$0.33$2.30
Distance from 52-week high-73.07%-88.42%
Analyst consensusbuystrong_buy
Avg. price target upside+1085.38%+1769.75%
Average volume1.17M838.83K
Shares outstanding136.14M19.43M
Employees29142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ONCY has outperformed TNXP by 20.2 percentage points over the past year.

About Oncolytics Biotech

ONCY stock →

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Tonix Pharmaceuticals

TNXP stock →

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees

ONCY vs TNXP FAQ

Which is bigger, Oncolytics Biotech or Tonix Pharmaceuticals?

Oncolytics Biotech (ONCY) is larger, with a market capitalization of $47.66M compared with $46.25M for Tonix Pharmaceuticals (TNXP).

Which stock has performed better over the past year, ONCY or TNXP?

ONCY returned -64.99% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.

Are Oncolytics Biotech and Tonix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons